^
Association details:
| Biomarker: | MET positive |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Tepmetko (tepotinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1082 / 26 - Effect of doublet treatment versus single-agent treatment in gastric cancers with/without MET amplification or a MET exon 14 skipping mutation
Published date:
03/15/2023
Excerpt:
Tepotinib alone was as effective as tepotinib plus paclitaxel in c-MET-positive GC cells….Our in vitro findings suggest that, compared to ramucirumab plus paclitaxel, tepotinib plus paclitaxel inhibits the growth of c-MET-positive GC cells…
Secondary therapy:
paclitaxel
